SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins selloff following reports of a major Binance security breach is the main pressure on Strategy, whose shares traders view as closely tied to BTC. The community is split between buying the dip and warning that crypto-security concerns, alongside Strategys revenue miss and CFO transition, could weigh further on the stock.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A run to a fresh 52-week high ahead of the upcoming Q3 report has traders focused on BRIUMVIs sales ramp and managements outlook; some point to earnings expectations, while others speculate about an unconfirmed buyout and short covering.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths Medicare add-on reimbursement could fall after the first quarter of 2027 has fueled concerns about CorMedixs pricing and revenue, alongside a sharp selloff. Traders disagree on how much weight to give DaVitas preliminary outlook, with some pointing to CMSs published reimbursement estimate while others see ongoing pressure ahead.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 77,177.65528711 USD and is down -1.08 over the last 24 hours. It is currently trading on 12773 active market(s) with $46,266,908,298.36 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

A reported major Binance security breach is driving concern about exchange safety, possible withdrawals and selling pressure across crypto. Traders are divided between expecting further downside from shaken confidence and viewing Bitcoins relative resilience as a buying opportunity, arguing the breach affects the exchange rather than Bitcoins network.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

Energy-sector strength and concern over oil-supply disruptions tied to Middle East tensionsespecially risks to shipping and refiningdominate the discussion around XLE. Traders point to the rally and energys relative strength as bullish, while others warn that diplomatic progress, profit-taking, or an overextended move could weigh on the fund.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Attention is focused on upcoming Q3 results and the Casgevy sales update, with traders debating whether rising patient starts and treatment-center expansion will translate into stronger collaboration revenue. The upcoming CTX310 clinical presentation is another key catalyst; sentiment is mixed between anticipation of data-driven progress and concern about the stocks decline and CFO transition.

Energy Transfer LP engages in natural gas pipeline transportation and transmission services. It operates through the following segments: Intrastate Transportation and Storage, Interstate Transportation and Storage, Midstream, NGL and Refined Products Transportation and Services, Crude Oil Transportation and Services, Investment in Sunoco LP, Investment in USAC, and All Other. The Intrastate Transportation and Storage segment owns and operates natural gas transportation pipelines. The Interstate Transportation and Storage segment includes transportation pipelines, storage facilities, and gathering systems and delivery of natural gas to industrial end-users and other pipelines. The Midstream segment consists of natural gas gathering, compression, treating, processing, storage, and transportation. The NGL and Refined Products Transportation segment engages in the operations transport, store and execute acquisition, and marketing activities utilizing a complementary network of pipelines, storage and blending facilities, and strategic off-take locations that provide access to multiple NGL markets. The Crude Oil Transportation and Services segment provides transportation, terminalling, acquisition, and marketing services to crude oil markets. The Investment in Sunoco LP segment refers to the distribution of motor fuels to independent dealers, distributors, and other commercial customers and the distribution of motor fuels to end-user customers at retail sites. The Investment in USAC segment offers compression services to its customers in connection with infrastructure applications including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. The company was founded by Kelcy L. Warren in 1996 and is headquartered in Dallas, TX.

Energy Transfer LP - Unit

Energy Transfer LP Unit

Energy Transfers strong quarterly results and outlook are fueling discussion of its potential to benefit from rising natural-gas demand for AI data centers and other power customers. Many traders are bullish on that growth and the distribution, while others are frustrated that the unit price has not responded more strongly.

Select Sector SPDR Trust (The) - State Street Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

XLK is drawing attention amid a sharp technology-sector selloff, with traders citing broad technical breakdowns and weakness in semiconductors and other tech groups. The conversation is mostly bearish, though some see the pullback as a potential buying opportunity or expect a bounce; confirmation of support remains a key debate.

Amp (AMP) is a cryptocurrency launched in 2020and operates on the Ethereum platform. Amp has a current supply of 99,720,267,351.28921674 with 89,781,193,103.18022 in circulation. The last known price of Amp is 0.0006528 USD and is up 0.85 over the last 24 hours. It is currently trading on 193 active market(s) with $5,174,420.89 traded over the last 24 hours. More information can be found at https://amp.xyz.

AMP Token

A sharp AMP rally and volume spike have traders speculating about renewed interest in the Flexa/Anvil payment-infrastructure thesis and AMPs collateral role. Others say there is no confirmed new catalyst and warn the move may be another short-lived pump.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbases post-earnings selloff is drawing attention as traders weigh weak underlying crypto-trading activity and a revenue shortfall against headline profitability, much of which they attribute to gains on crypto holdings. A Bitcoin slide and Binance hack concerns are adding pressure, though some traders view the decline as an overreaction or buying opportunity.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced it granted inducement equity awards to two newly-hired employees.On October 19, 2026, the Compensation Committee...

AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced the presentation of a poster detailing the design of its planned Phase 2...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX)PR NewswireNEW YORK, Oct. 12, 2026NEW YORK, Oct. 12, 2026...

AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage pharmaceutical company focused on the discovery and development of small molecule therapeutics derived from its boron chemistry platform, today announced that the Gates Foundation has awarded an extension of funding to support AN2...

AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)

AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced it granted inducement equity awards to Cameron Trenor, M.D., the Companys newly-appointed Chief Medical...

AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that four abstracts highlighting clinical and nonclinical data supporting the...

AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the appointment of Cameron Trenor, M.D., as Chief Medical Officer. Dr. Trenor is an accomplished...

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the second quarter ended June 30, 2026. AN2 will have three...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX) PR Newswire NEW YORK, July 20, 2026 NEW YORK, July 20, 2026...

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease

AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results from two studies evaluating the Companys oral CPSF3 inhibitor, AN2-502998, for the treatment of...

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley in 2017 and is headquartered in Menlo Park, CA.

AN2 Therapeutics Inc

ANTX Stock Records Biggest Ever Single Day Gain, Surges 500% Over Past Four Sessions – What Triggered This Smashing Rally?

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>AN2 Therapeutics is expected to sell more than eight million shares of common stock at $2.85 per share.</li><li>The private placement includes participation from institutional investors such as Coastlands Capital, Commodore Capital, and Vivo Capital.</li><li>The stock has gained more than&nbsp;500% over four sessions since the company announced positive results for its blood cancer treatment.</li></ul>Shares of AN2 Therapeutics (ANTX) surged more than 110% on Monday, after the clinical-stage biopharmaceutical company announced that it signed a securities purchase agreement for a private placement expected to raise about $40 million in gross proceeds.<a href="https://stocktwits.com/symbol/ANTX">ANTX shares</a> recorded their biggest-ever intraday gains.As part of the deal, AN2 Therapeutics will sell 8.25 million shares of common stock at $2.85 per share, which was also the stock’s closing price on Friday. The company also offered investors the option to purchase pre-funded warrants to acquire up to 5.79 million additional shares at nearly the same price, with an exercise price of&nbsp;$0.00001 per share.The private placement is expected to close on March 10, 2026, and includes participation from institutional investors such as Coastlands Capital, Commodore Capital, and Vivo Capital, along with other new and existing shareholders. AN2 Therapeutics did not disclose how it plans to use the proceeds from the offering.<h2 class="st-heading-2">500% Rally After Epetraborole Update</h2>The stock has been on an extraordinary rally, adding nearly 500% over four sessions since the company announced plans to further develop its drug epetraborole into a Phase 2 proof-of-concept study for patients with Polycythemia Vera (PV) who rely on phlebotomy treatments.PV is a blood cancer that causes the bone marrow to produce too many red blood cells, increasing the risk of serious complications such as blood clots.Last week, AN2 Therapeutics said that its oral epetraborole produced consistent and sustained reductions in hematocrit across several studies involving healthy volunteers and other patient groups. The company expects to begin the Phase 2 study in the third quarter of 2026 and plans to provide initial trial updates by the following quarter.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained ‘extremely bullish’ over the past 24 hours, amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/ANTX_jpg_31ad151992.webp" alt="ANTX.jpg">One user highlighted the various resistance levels, speculating that the stock could climb as high as $108.<stembedurl>https://stocktwits.com/M105/message/647014265</stembedurl>However, another expressed confusion over the “bullish excitement.”<stembedurl>https://stocktwits.com/Tradeforlosses/message/647018987</stembedurl>Year-to-date, the stock has gained more than 400%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/iran-warns-of-crude-hitting-200-a-barrel-if-energy-infrastructure-is-targeted-report/cZdVpreRIIr">Iran Warns Of Crude Hitting $200 A Barrel If Energy Infrastructure Is Targeted: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

AN2 Therapeutics shares more than doubled in value on Monday after the company announced a private placement to raise about $40 million.

iShares Micro-Cap ETF

Vanguard Total Stock Market ETF

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$4.53
Prev Close	$4.69
Open	$4.66
Dividend Yield	0.00%
50-Day Moving Average	$4.90
Beta	0.73
Avg. Volume	237,912.97
PE Ratio	-4.22

52-Week High	$7.19
52-Week Low	$1.00
Market Capitalization	$170.95M
EPS (Annual)	-$1.16
Price to Book	2.17
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

ANTX Fundamentals